Erratum: Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines (Annals of Oncology (2012) 23(7) (1788–1795), (S092375341937989X), (10.1093/annonc/mdr484));Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines

Annals of Oncology

Volumn 23, Issue 7, 2012, Pages 1788-1795

  Collins, D M ^a   O'donovan, N ^a   Mcgowan, P M ^b   O'sullivan, F ^a   Duffy, M J ^c   Crown, J ^a,c  

^a DUBLIN CITY UNIVERSITY   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

ADCC; ERBB2; HER 2 low; HER 2 non amplified breast cancer; Trastuzumab

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG RESEARCH; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE IMAGING; HUMAN; HUMAN CELL; HUMAN TISSUE; MOLECULAR IMAGING; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 84864310710     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds612     Document Type: Erratum

References (46)

1. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 2354785: 177-182.
2. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 251: 118-145.
3. Seshadri R, Firgaira FA, Horsfall DJ et al. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J Clin Oncol 1993; 1110: 1936-1942.
4. Tandon AK, Clark GM, Chamness GC et al. HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 1989; 78: 1120-1128.
5. Cobleigh MA, Vogel CL, Tripathy D et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2- overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 179: 2639-2648.
6. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 34411: 783-792.
7. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 35316: 1659-1672.
8. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 35316: 1673-1684.
9. Pohlmann PR, Mayer IA, Mernaugh R Resistance to trastuzumab in breast cancer. Clin Cancer Res 2009; 1524: 7479-7491.
10. Arnould L, Gelly M, Penault-Llorca F et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?. Br J Cancer 2006; 942: 259-267.
11. Mimura K, Kono K, Hanawa M et al. Trastuzumab-mediated antibody-dependent cellular cytotoxicity against esophageal squamous cell carcinoma. Clin Cancer Res 2005; 1113: 4898-4904.
12. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000; 64: 443-446.
13. Cooley S, Burns LJ, Repka T, Miller JS Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu. Exp Hematol 1999; 2710: 1533-1541.
14. Marty M, Cognetti F, Maraninchi D et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005; 2319: 4265-4274.
15. Seidman AD, Berry D, Cirrincione C et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 2008; 2610: 1642-1649.
16. Slamon DJ, Eiermann W, Robert NJ et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. [abstract]. Breast Cancer Res Treat 2005; 94 (Suppl 1): S5.
17. Paik S, Kim C, Jeong J et al. Benefit from adjuvant trastuzumab may not be confined to patients with IHC 3 + and /or FISH-positive tumours: central testing results from NSABP B-31. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I. 2007; 25 (18S Suppl): 511.
18. Paik S, Kim C, Wolmark N HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med 2008; 35813: 1409-1411.
19. Perez EA, Reinholz MM, Hillman DW et al. HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. J Clin Oncol 2010; 2828: 4307-4315.
20. Mozaffari F, Lindemalm C, Choudhury A et al. NK-cell and T-cell functions in patients with breast cancer: effects of surgery and adjuvant chemo- and radiotherapy. Br J Cancer 2007; 971: 105-111.
21. Gennari R, Menard S, Fagnoni F et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 2004; 1017: 5650-5655.
22. Spiridon CI, Guinn S, Vitetta ES A comparison of the in vitro and in vivo activities of IgG and F(ab')2 fragments of a mixture of three monoclonal anti-Her-2 antibodies. Clin Cancer Res 2004; 1010: 3542-3551.
23. Sliwkowski MX, Lofgren JA, Lewis GD et al. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 1999; 264 Suppl 1260-70.
24. Varchetta S, Gibelli N, Oliviero B et al. Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. Cancer Res 2007; 6724: 11991-11999.
25. Raulet DH, Vance RE Self-tolerance of natural killer cells. Nat Rev Immunol 2006; 67: 520-531.
26. Drexler HG. The Leukemia-Lymphoma Cell Lines FactsBook 2000San Diego, CA: Academic Press.
27. Martin A, Clynes M Comparison of 5 microplate colorimetric assays for in vitro cytotoxicity testing and cell proliferation assays. Cytotechnology 1993; 111: 49-58.
28. Wu X, Liu H, Liu J et al. Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots. Nat Biotechnol 2003; 211: 41-46.
29. Finn RS, Dering J, Ginther C et al. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/ "triple-negative" breast cancer cell lines growing in vitro. Breast Cancer Res Treat 2007; 1053: 319-326.
30. Lyon E, Millson A, Lowery MC et al. Quantification of HER2/neu gene amplification by competitive pcr using fluorescent melting curve analysis. Clin Chem 2001; 475: 844-851.
31. O'Brien NA, Browne BC, Chow L et al. Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib. Mol Cancer Ther 2010; 96: 1489-1502.
32. Lewis GD, Figari I, Fendly B et al. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol Immunother 1993; 374: 255-263.
33. Pratesi G, Petrangolini G, Tortoreto M et al. Antitumor efficacy of trastuzumab in nude mice orthotopically xenografted with human pancreatic tumor cells expressing low levels of HER-2/neu. J Immunother 2008; 316: 537-544.
34. El-Sahwi K, Bellone S, Cocco E et al. In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma. Br J Cancer 2010; 1021: 134-143.
35. Yamauchi C, Fujii S, Kimura T et al. E-cadherin expression on human carcinoma cell affects trastuzumab-mediated antibody-dependent cellular cytotoxicity through killer cell lectin-like receptor G1 on natural killer cells. Int J Cancer 2011; 1289: 2125-2137.
36. Borgerding A, Hasenkamp J, Engelke M et al. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression. Exp Hematol 2010; 383: 213-221.
37. Hsiao YW, Liao KW, Hung SW, Chu RM Tumor-infiltrating lymphocyte secretion of IL-6 antagonizes tumor-derived TGF-beta 1 and restores the lymphokineactivated killing activity. J Immunol 2004; 1723: 1508-1514.
38. Olsen DA, Ostergaard B, Bokmand S et al. HER-2 protein concentrations in breast cancer cells increase before immunohistochemical and fluorescence in situ hybridization analysis turn positive. Clin Chem Lab Med 2007; 452: 177-182.
39. Whiteside TL, Vujanovic NL, Herberman RB Natural killer cells and tumor therapy. Curr Top Microbiol Immunol 1998; 230: 221-244.
40. Beano A, Signorino E, Evangelista A et al. Correlation between NK function and response to trastuzumab in metastatic breast cancer patients. J Transl Med 2008; 6: 25.
41. Musolino A, Naldi N, Bortesi B et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008; 2611: 1789-1796.
42. Hurvitz SA, Betting D, Stern HM et al. Analysis of Fc gamma receptor IIA & IIIA polymorphisms: correlation with outcome in trastuzumab-treated HER2/Neu amplified early and metastatic breast cancer patients. Cancer Res 2009; 69Suppl 24(Abstr 64).
43. Korkaya H, Wicha MS Selective targeting of cancer stem cells: a new concept in cancer therapeutics. BioDrugs 2007; 215: 299-310.
44. Korkaya H, Wicha MS HER-2, notch, and breast cancer stem cells: targeting an axis of evil. Clin Cancer Res 2009; 156: 1845-1847.
45. Ignatiadis M, Desmedt C, Sotiriou C et al. HER-2 as a target for breast cancer therapy. Clin Cancer Res 2009; 156: 1848-1852.
46. Press MF, Finn RS, Cameron D et al. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer. Clin Cancer Res 2008; 1423: 7861-7870.